Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOSE-PD: Intranasal Insulin and Glutathione in Parkinson's Disease
NCT05266417Phase 2Recruiting
- Sponsor
- Gateway Institute for Brain Research
- Start
- Feb 2022
- Primary completion
- Sep 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Generex Oral-lyn and glutathione in Parkinson's disease (PD) (2 arms), sponsored by Gateway Institute for Brain Research. Primary endpoint: Verbal Fluency at 24 weeks. Started Feb 2022; status: recruiting.
02
Drugs
Generex Oral-lynglutathione
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05266417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05266417.